G24.01 Drug induced subacute dyskinesia

Name of the Condition

• Drug induced subacute dyskinesia (ICD-10 Code: G24.01)

Summary

Drug induced subacute dyskinesia is a movement disorder characterized by involuntary, repetitive movements that develop gradually over days to weeks following exposure to certain medications. These movements typically involve the face, trunk, or limbs and are often reversible with appropriate intervention. The condition arises from disrupted dopamine signaling in the basal ganglia, leading to abnormal motor control.

Causes

Drug induced subacute dyskinesia is caused by adverse reactions to medications, most commonly dopamine receptor antagonists such as antipsychotics (e.g., typical and atypical neuroleptics) and antiemetics (e.g., metoclopramide). Other implicated drugs include certain antidepressants and calcium channel blockers. The onset is typically subacute, occurring days to weeks after initiating or adjusting the medication.

Risk Factors

• Use of dopamine receptor antagonists, including antipsychotics and antiemetics.
• High doses or rapid titration of these medications.
• Prolonged therapy with implicated drugs.
• Individual susceptibility, such as younger age or genetic predisposition.

Symptoms

• Involuntary, repetitive movements (e.g., lip smacking, tongue protrusion, or limb flailing).
• Abnormal postures or sustained muscle contractions.
• Movements that worsen with stress or voluntary action.
• Difficulty with voluntary movements (e.g., speaking, eating, or walking).
• Discomfort or pain in affected areas.

Diagnosis

Diagnosis is based on a temporal relationship between medication exposure and symptom onset, along with a neurological examination to identify characteristic involuntary movements. A thorough medication history is critical. Additional tests, such as MRI or blood work, may be performed to rule out other conditions, but imaging is often normal in isolated cases.

Treatment Options

Treatment involves discontinuing or reducing the offending medication, if clinically feasible. Symptomatic management may include switching to a lower-risk agent, using medications like tetrabenazine or valbenazine to reduce dyskinesia, or initiating physical therapy to improve motor control. Botulinum toxin injections may be considered for focal symptoms.

Prognosis and Follow-Up

Prognosis is generally favorable with prompt intervention, as symptoms often resolve partially or completely after discontinuing the causative drug. Follow-up is necessary to monitor for symptom resolution and to adjust treatment plans. Some individuals may experience persistent or recurrent symptoms, requiring long-term management.

Complications

• Persistent or worsening dyskinesia despite treatment.
• Functional impairment affecting daily activities (e.g., eating, speaking).
• Psychological distress due to visible movements.
• Increased risk of falls or injury from uncontrolled movements.

Lifestyle & Prevention

• Avoid or minimize use of high-risk medications when possible.
• Monitor for early signs of dyskinesia during medication initiation or dose changes.
• Engage in regular physical activity to maintain mobility and coordination.
• Use assistive devices (e.g., walkers) if balance or gait is affected.

When to Seek Professional Help

Seek immediate medical attention if involuntary movements are severe, sudden, or accompanied by difficulty breathing, swallowing, or speaking. Prompt evaluation is essential to identify the cause and initiate treatment to prevent complications.

Tips for Medical Coders

Document the temporal relationship between medication exposure and symptom onset, as well as the specific medications involved. Include details about the onset (subacute) and distribution of movements (e.g., facial, limb) to support accurate coding. Ensure the diagnosis aligns with the clinical presentation and medication history.